← ANALYST RATINGS · TIPRANKS
Bristol-Myers Squibb (BMY): analyst forecast and price target
Analyst consensus
Moderate Buy9 Buy12 Hold1 Sell
Ratings of 22 analysts in the last 3 months12-month forecast
Based on 22 price targets given in the last 3 months, the average target is $66.60, the highest $82.00, the lowest $41.00. The average is +11.5% from the last price of $59.75.
Analyst ratings 25
| Analyst | Firm | Price target | Rating | Upside | Action | Date | Move vs SPY | |
|---|---|---|---|---|---|---|---|---|
| Trung Huynh★★★★★★★★★★#475 · hits 76% · avg +21.9% | RBC Capital | $64.00 | Hold | +7.1% | Reiterated | 16.10.26on TipRanks 21:45 | after the close | ↗ |
| AI xAi Drug Manufacturers - GeneralxAI Grok-3 | TipRanks - xAI | $73.00 → $65.00−11.0% | Buy | +8.8% | Reiterated | 15.10.26on TipRanks Oct 14 23:05 | — | |
| AI DeepSeek Drug Manufacturers - GeneralDeepSeek R1-0528 | TipRanks - DeepSeek | $73.00 → $65.00−11.0% | Buy | +8.8% | Reiterated | 15.10.26on TipRanks Oct 14 23:05 | — | |
| AI OpenAI Drug Manufacturers - GeneralOpenAI 4o | TipRanks - OpenAI | $73.00 → $63.00−13.7% | Buy | +5.4% | Reiterated | 15.10.26on TipRanks Oct 14 23:05 | — | |
| AI Anthropic Drug Manufacturers - GeneralAnthropic Opus-4.1 | TipRanks - Anthropic | $67.00 → $60.00−10.4% | Hold | +0.4% | Reiterated | 15.10.26on TipRanks Oct 14 23:05 | — | |
| AI Google Drug Manufacturers - GeneralGemini 2.5Pro | TipRanks - Google | $73.00 → $65.00−11.0% | Buy | +8.8% | Reiterated | 15.10.26on TipRanks Oct 14 23:05 | — | |
| AI PerPlexity Drug Manufacturers - GeneralPerPlexity SonarPro | TipRanks - PerPlexity | $76.00 → $65.00−14.5% | Buy | +8.8% | Upgrade | 15.10.26on TipRanks Oct 14 23:05 | — | |
| Srikripa Devarakonda★★★★★★★★★★#200 · hits 62% · avg +26.3% | Truist Financial | $70.00 | Buy | +17.2% | Reiterated | 13.10.26on TipRanks 07:50 | −1.6%next day +5.7% | ↗ |
| Geoff Meacham★★★★★★★★★★#407 · hits 60% · avg +15.3% | Citi | $70.00 | Hold | +17.2% | Reiterated | 13.10.26on TipRanks 07:15 | −1.6%next day +5.7% | ↗ |
| David Amsellem★★★★★★★★★★#347 · hits 62% · avg +15.7% | Piper Sandler | $82.00 | Buy | +37.2% | Reiterated | 13.10.26on TipRanks 07:10 | −1.6%next day +5.7% | ↗ |
| Mohit Bansal★★★★★★★★★★#754 · hits 60% · avg +10.9% | Wells Fargo | $65.00 → $60.00−7.7% | Hold | +0.4% | Assigned | 13.10.26on TipRanks 06:11 | −1.6%next day +5.7% | ↗ |
| Emily Field★★★★★★★★★★#5009 · hits 45% · avg +1.9% | Barclays | $75.00 | Buy | +25.5% | Reiterated | 13.10.26on TipRanks 04:50 | −1.6%next day +5.7% | ↗ |
| Asad Haider★★★★★★★★★★#1137 · hits 82% · avg +22.7% | Goldman Sachs | $61.00 → $63.00+3.3% | Hold | +5.4% | Reiterated | 12.10.26on TipRanks Oct 13 09:45 | −2.5%next day −1.6% | ↗ |
| Terence Flynn★★★★★★★★★★#815 · hits 60% · avg +10.8% | Morgan Stanley | $41.00 | Sell | −31.4% | Reiterated | 12.10.26on TipRanks 17:45 | −1.6%next day +5.7% | ↗ |
| Akash Tewari★★★★★★★★★★#649 · hits 57% · avg +13.5% | Jefferies | $73.00 → $76.00+4.1% | Buy | +27.2% | Reiterated | 12.10.26on TipRanks 15:55 | −2.5%next day −1.6% | ↗ |
| Matt Phipps★★★★★★★★★★#2652 · hits 48% · avg +4.8% | William Blair | — | Hold | — | Reiterated | 12.10.26on TipRanks 14:10 | −2.5%next day −1.6% | ↗ |
| Evan Seigerman★★★★★★★★★★#856 · hits 59% · avg +9.3% | BMO Capital | $60.00 | Hold | +0.4% | Reiterated | 12.10.26on TipRanks 13:20 | −2.5%next day −1.6% | ↗ |
| Jason Gerberry★★★★★★★★★★#184 · hits 63% · avg +21.5% | Bank of America Securities | $71.00 → $66.00−7.0% | Buy | +10.5% | Reiterated | 09.10.26on TipRanks 06:50 | −1.4%next day −2.5% · 5 days +3.0% | ↗ |
| Seamus Fernandez★★★★★★★★★★#129 · hits 66% · avg +30.6% | Guggenheim | $75.00 | Buy | +25.5% | Reiterated | 08.10.26on TipRanks Oct 9 08:50 | +0.2%next day −1.4% · 5 days +1.9% | ↗ |
| Louise Chen★★★★★★★★★★#1899 · hits 52% · avg +5.9% | Scotiabank | $60.00 | Hold | +0.4% | Assigned | 08.10.26on TipRanks 08:10 | +0.2%next day −1.4% · 5 days +1.9% | ↗ |
| Chris Schott★★★★★★★★★★#1915 · hits 58% · avg +5.7% | J.P. Morgan | $73.00 | Buy | +22.2% | Reiterated | 08.10.26on TipRanks 07:55 | +0.2%next day −1.4% · 5 days +1.9% | ↗ |
| Carter Gould★★★★★★★★★★#2194 · hits 53% · avg +6.3% | Cantor Fitzgerald | $59.00 → $53.00−10.2% | Hold | −11.3% | Assigned | 08.10.26on TipRanks 07:10 | +0.2%next day −1.4% · 5 days +1.9% | ↗ |
| Michael Yee★★★★★★★★★★#3077 · hits 49% · avg +3.8% | UBS | $80.00 | Buy | +33.9% | Reiterated | 07.10.26on TipRanks Oct 8 06:15 | +0.4%next day +0.2% · 5 days +0.3% | ↗ |
| David Risinger★★★★★★★★★★#64 · hits 65% · avg +33.1% | Leerink Partners | $73.00 → $59.00−19.2% | Hold | −1.3% | Reiterated | 05.10.26on TipRanks 08:12 | −4.5%next day +0.8% · 5 days −2.5% | ↗ |
| Rajesh Kumar★★★★★★★★★★#1587 · hits 62% · avg +14.5% | HSBC | $60.00 → $65.00+8.3% | Hold | +8.8% | Reiterated | 10.09.26on TipRanks 06:30 | −0.4%next day −1.0% · 5 days −2.1% | ↗ |
| Courtney Breen★★★★★★★★★★#1339 · hits 85% · avg +18.9% | Bernstein | — | Hold | — | Reiterated | 20.08.26on TipRanks Aug 21 07:30 | −2.3%next day +1.9% · 5 days +1.1% | ↗ |
| Jasper Hellweg★★★★★★★★★★#2291 · hits 57% · avg +7.4% | Argus Research | $75.00 | Buy | +25.5% | Upgrade | 04.08.26on TipRanks Aug 5 08:01 | −1.2%next day −3.2% · 5 days −3.4% | ↗ |
| Unknown Analyst | Berenberg Bank | $60.00 → $65.00+8.3% | Hold | +8.8% | Reiterated | 03.08.26on TipRanks Aug 5 08:01 | −1.2%next day −1.2% · 5 days −3.0% | ↗ |
| Unknown Analyst | Jefferies | $70.00 → $73.00+4.3% | Buy | +22.2% | Reiterated | 01.06.26on TipRanks Jun 2 08:50 | −4.2%next day −1.0% · 5 days +3.7% | ↗ |
| Unknown Analyst | TD Cowen | $57.00 | Hold | −4.6% | Reiterated | 18.05.26on TipRanks Jun 5 08:01 | +0.6%next day +2.4% · 5 days −0.4% | |
| Unknown Analyst | Erste Group | — | Hold | — | Reiterated | 01.04.26on TipRanks Apr 2 16:20 | +1.0%next day −2.5% · 5 days −6.4% | ↗ |
| No ratings for this filter. | ||||||||
The latest rating of each analyst in the last 12 months, as TipRanks lists them. Every rating kept, earlier ones included
Best analysts covering Bristol-Myers Squibb
TipRanks picks them by their record on this stock; the figures under the name are their record across all their ratings.
Most accurate
Most profitable
How the average price target moved
The average target of all analysts (their ratings of the 3 months before) on each day, the top analysts’ dashed, against the price; the site keeps this record since 1 October 2026. On 01.10.26: target $67.22 at a price of $62.40 (+7.7%); now: $66.60 at $59.75 (+11.5%).
PriceAverage targetTop analysts’ target
Recommendation trend
Strong BuyBuyHoldSell
| Rating | 05.26 | 06.26 | 07.26 | 08.26 | 09.26 | 10.26 |
|---|---|---|---|---|---|---|
| Strong Buy | 0 | 0 | 0 | 0 | 0 | 0 |
| Buy | 14 | 19 | 22 | 21 | 16 | 16 |
| Hold | 30 | 27 | 30 | 28 | 33 | 31 |
| Sell | 1 | 1 | 2 | 2 | 3 | 4 |
Earnings and sales forecast
Next report: 29.10.26 (Q3 2026, date not confirmed)
Earnings per share
Next quarter’s EPS estimate — $1.09 (from $0.98 to $1.18). Last quarter: $2.04.
Sales
Next quarter’s sales estimate — $12.7B (from $12.5B to $13.1B). Last quarter: $13.0B.
Best top-analyst consensus in the sector · Healthcare
About Bristol-Myers Squibb
- CEO: Christopher Boerner
- Employees: 32,500
- Route 206 & Province Line Road, Princeton, NJ, 08543, US
- www.bms.com
Bristol-Myers Squibb Company operates as a global biopharmaceutical entity, actively involved in the research, development, licensing, production, and worldwide commercialization of its medicinal portfolio. The company's therapeutic areas span hematology, oncology, cardiovascular health, immunology, fibrotic conditions, neuroscience, and infectious diseases like COVID-19. Its significant pharmaceutical offerings include Revlimid, an oral immunomodulatory agent for multiple myeloma, and Eliquis, an oral anticoagulant crucial for reducing stroke risk and systemic embolism in non-valvular atrial fibrillation, as well as treating deep vein thrombosis and pulmonary embolism. The portfolio also features Opdivo, utilized across various anti-cancer indications; Pomalyst/Imnovid, prescribed for multiple myeloma patients; and Orencia, targeting active rheumatoid arthritis and psoriatic arthritis in adults. Other key therapies are Sprycel, employed in the management of Philadelphia chromosome-positive chronic myeloid leukemia; Yervoy, indicated for patients with unresectable or metastatic melanoma; and Abraxane, a protein-bound chemotherapy formulation. Furthermore, Bristol-Myers Squibb offers Reblozyl, addressing anemia in adult patients with beta thalassemia; Empliciti, another treatment option for multiple myeloma; and Zeposia, designed to treat relapsing forms of multiple sclerosis. Revolutionary treatments like Breyanzi, a CD19-directed genetically modified autologous T cell immunotherapy for adult patients battling relapsed or refractory large B-cell lymphoma, are also part of its lineup. Completing its product range are Inrebic, an oral kinase inhibitor specifically for adult myelofibrosis, and Onureg, used in the treatment of adult patients with acute myeloid leukemia (AML). Bristol-Myers Squibb distributes its pharmaceutical products through a diverse network encompassing wholesalers, distributors, pharmacies, retail outlets, hospitals, clinics, and governmental organ
Data from the stock’s TipRanks forecast page, read 12 min ago. It is read again as soon as a new rating appears and at least every 8 hours. TipRanks ↗